Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028

Whitehawk Therapeutics, Inc.

2025-Q1 EPS reported $1.83 revenue$7,145,000

Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.
Revenue $7.1M from FYARRO sales through March 25, 2025, date of divestiture to Kaken for $102.4M.
Cash and equivalents $231.1M at March 31, 2025 (vs $47.2M Dec 31, 2024) after closing $100M PIPE.
Expects cash of ~$185M after transaction payments, funding operations into 2028.
Oncology ADC pipeline: three assets targeting PTK7, MUC16, SEZ6; first IND on track for Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.